ClinicalTrials.gg
CompletedNCT02862210LithiumUpdated Feb 3, 2025Results posted

Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia

A Phase 2 interventional study of Lithium Carbonate and Placebo in Frontotemporal Dementia (FTD), sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-02-03.

Sponsored by Columbia University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Enrollment
54th of 66
17 · median 60
Started
2017
with 7 others
Phase 2
14 of 103
4 open now
Registered
34th of 103
by date
Lead sponsor
3 of 103
Columbia University

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 54th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2017, is one of 14 in phase 2, and was the 34th registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

Frontotemporal dementia (FTD) is a progressive neurodegenerative illness that affects the frontal and anterior temporal lobes of the brain. Changes in behavior, including agitation, aggression, and repetitive behaviors, are common symptoms in FTD. The investigators currently do not have good medications to treat these symptoms in FTD, and the medications the investigators use often have side effects. In this project, the investigators will test the use of low-dose lithium, compared to a placebo pill, for the treatment of behavioral symptoms in FTD. Lithium greatly reduces the behavioral symptoms of bipolar disorder, and many have found low-dose lithium to be well-tolerated in patients with dementia. Lithium appears to inhibit the creation of a protein involved in many cases of FTD called tau.

Read the detailed description

Behavioral symptoms of Frontotemporal dementia (FTD), including agitation, aggression, and inappropriate repetitive behaviors are common, distressing to patients and caregivers, often lead to institutionalization, and can be very difficult and expensive to treat. There is a dearth of medication for treating these symptoms in FTD. Typically, antidepressants and antipsychotic medications are prescribed - which low efficacy and, with the latter class, carry serious adverse effects such as parkinsonism and increased cardiovascular-related mortality. The investigators propose a study of the efficacy of lithium carbonate compared to placebo in the treatment of agitation, aggression, and inappropriate repetitive behaviors in 60 patients with FTD in a randomized, double-blind, two-arm parallel 12-week trial. Lithium is a highly effective treatment for mania and symptoms of agitation or aggression in bipolar disorder. It also inhibits tau aggregation and phosphorylation, leading to considerable interest in its use as a disease-modifying treatment for tauopathies such as FTD and Alzheimer's disease. Unfortunately, earlier trials using typical doses (i.e., doses prescribed for treatment of bipolar disorder) showed high incidence of serious adverse effects (including confusion and delirium). For this proposed study the investigators will: 1) use lower doses and lower target serum concentrations than have preceding trials (shown in preliminary data from a Columbia study and data from other labs to be well-tolerated) and 2) target behavioral symptoms rather than cognitive outcomes.

03

Conditions studied

  • Frontotemporal Dementia (FTD)

Keywords

  • Lithium
  • Lithium Carbonate
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-85
  • A diagnosis of behavioral variant FTD (bv-FTD) or semantic variant Primary Progressive Aphasia (sv-PPA, which is generally accompanied by a behavioral syndrome), or agrammatic/non-fluent Primary Progressive Aphasia (nfv-PPA) with behavioral symptoms
  • Neuropsychiatric Inventory (NPI) agitation/aggression subscale score ≥4 or disinhibition subscale score ≥ 4 or repetitive behavior subscale ≥ 4 or total score ≥ 6. On each subscale, a score higher than 4 represents moderate to severe symptoms
  • Folstein (MMSE) score 5-26/30
  • An study partner (usually a family member) is required to provide information during interviews about the patient
  • Capacity to consent. Subjects without capacity to consent must have capacity to appoint a surrogate
  • Structural MRI or CT scan after symptom onset

Exclusion criteria

Exclusion Criteria:

  • Medical or history of intolerability to lithium, falls in the last month, current abnormal thyroid functions (T3, T4 or thyroid stimulating hormone (TSH); treated hypothyroidism with normal thyroid function tests will not lead to exclusion), creatinine level > 1.5 mg/100 ml or \< 44 ml/min/1.73m2 will also lead to exclusion
  • The diagnosis of bipolar disorder or schizophrenia or schizoaffective disorder
  • Alcohol or substance use disorder in the prior 6 months
  • Current diagnosis of other major neurological disorder, e.g., Alzheimer's Disease (AD), stroke with residual clinical deficits, multiple sclerosis, Parkinson's disease. Subjects with MRI or CT evidence of cerebrovascular disease but without clinical signs of stroke will be included
  • Sitting blood pressure > 150/90 mm Hg, unstable cardiac disease, severe or unstable medical illness
  • Use of medications, including diuretics, known to have adverse effects when combined with lithium. Use of antipsychotic medications will be permitted
  • Current major depression or suicidality or dangerous behavior with risk of harm to self and others
  • interval (QTc) interval > 460 ms at the time of baseline (EKG)
  • Woman of
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Lithium carbonate

    Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.

    Drug: Lithium Carbonate

  • Placebo comparator
    Placebo

    Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.

    Drug: Placebo

Interventions

  • Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.

    Also known as: Lithobid

  • DrugPlacebo

    Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.

06

What researchers measure

Primary outcomes

  1. Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI)

    The NPI is a scale designed to assess behavioral changes due to neurological illness. It uses a standardized caregiver interview to rate patient symptoms in a variety of domains, including "Agitation/Aggression." Each domain includes a number of questions about potential specific symptoms, and then asks the caregiver to rate symptom frequency (1, occasionally, to 4, very frequently) as well as symptom severity (1, mild, to 3, severe). Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms. The study aims to test the effect of lithium on agitation/aggression as compared to placebo by testing whether participants taking lithium show a greater reduction in their NPI "Agitation/Aggression" domain score over the course of the trial.

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Responders in the Lithium and Placebo Groups

    Responder defined as a 30% decrease in NPI core score (sum of domain scores for "Agitation/Aggression" and "Aberrant Motor Behavior") plus a Clinical Global Impression (CGI) Change score of much improved or very much improved (CGI based on these behavioral symptoms only).

    Time frame: 12 weeks

Other outcomes

  1. Change in Motor Symptoms as Measured by the NPI

    NPI domain "Aberrant Motor Behaviors" will be observed to test the effect of lithium on repetitive behaviors as compared to placebo, by examining whether participants taking lithium show a greater reduction in their "Aberrant Motor Behaviors" NPI domain score. Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms.

    Time frame: 12 weeks

  2. Presence of Adverse Events as Measured by the Treatment Emergent Symptoms Scale (TESS)

    The tolerability of low-dose lithium by assessing emergent side effects over the course of the 12-week trial will be assessed. The side effects will be captured with TESS in which 30 symptoms are rated either "Absent," "Mild," "Moderate," or "Severe." The change in TESS score from baseline to week 12 will be observed. Total scores range from 0 to 96 with a higher score indicating a worse outcome.

    Time frame: 12 weeks

  3. The Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Agitation/Aggression" Score

    The baseline serum BDNF levels as a potential baseline predictor of lithium treatment response and an increase from pre to post-treatment BDNF levels as a potential biomarker correlate of improvement in symptoms (as measured by the NPI) will be explored. The mean change of NPI "Agitation/Aggression" score as a function of BDNF level change from baseline to 12 weeks will be reported. Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms.

    Time frame: Baseline and 12 weeks

  4. The Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Aberrant Motor Behavior" Score

    The baseline serum BDNF levels as a potential baseline predictor of lithium treatment response and an increase from pre to post-treatment BDNF levels as a potential biomarker correlate of improvement in symptoms (as measured by the NPI) will be explored. Aberrant motor behavior is characterized by repetitive movements and inability to sit still. The mean change of NPI Aberrant Motor Behavior score as a function of BDNF level change from baseline to 12 weeks will be reported. Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms.

    Time frame: Baseline and 12 weeks

07

Results

Posted Feb 3, 2025

Participant flow

A total of 17 participants signed a consent form. One participant was a screen failure, resulting in randomization of 16 participants.

Participant flow — Overall Study
MilestoneLithium CarbonatePlacebo
Started97
Completed97
Not completed00

Outcome measures

PrimaryChange in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI)

The NPI is a scale designed to assess behavioral changes due to neurological illness. It uses a standardized caregiver interview to rate patient symptoms in a variety of domains, including "Agitation/Aggression." Each domain includes a number of questions about potential specific symptoms, and then asks the caregiver to rate symptom frequency (1, occasionally, to 4, very frequently) as well as symptom severity (1, mild, to 3, severe). Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms. The study aims to test the effect of lithium on agitation/aggression as compared to placebo by testing whether participants taking lithium show a greater reduction in their NPI "Agitation/Aggression" domain score over the course of the trial.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI)
score on a scaleLithium CarbonatePlacebo
Change in Agitation and Aggression as Measured by the Neuropsychiatric Inventory Scale (NPI)7.14 ± 1.15.75 ± 1.28
SecondaryNumber of Responders in the Lithium and Placebo Groups

Responder defined as a 30% decrease in NPI core score (sum of domain scores for "Agitation/Aggression" and "Aberrant Motor Behavior") plus a Clinical Global Impression (CGI) Change score of much improved or very much improved (CGI based on these behavioral symptoms only).

Time frame:
12 weeks
Reported as:
Number · participants
Number of Responders in the Lithium and Placebo Groups
participantsLithium CarbonatePlacebo
Number of Responders in the Lithium and Placebo Groups00
Other pre-specifiedChange in Motor Symptoms as Measured by the NPI

NPI domain "Aberrant Motor Behaviors" will be observed to test the effect of lithium on repetitive behaviors as compared to placebo, by examining whether participants taking lithium show a greater reduction in their "Aberrant Motor Behaviors" NPI domain score. Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Change in Motor Symptoms as Measured by the NPI
score on a scaleLithium CarbonatePlacebo
Change in Motor Symptoms as Measured by the NPI6.83 ± 0.958.8 ± 1.23
Other pre-specifiedPresence of Adverse Events as Measured by the Treatment Emergent Symptoms Scale (TESS)

The tolerability of low-dose lithium by assessing emergent side effects over the course of the 12-week trial will be assessed. The side effects will be captured with TESS in which 30 symptoms are rated either "Absent," "Mild," "Moderate," or "Severe." The change in TESS score from baseline to week 12 will be observed. Total scores range from 0 to 96 with a higher score indicating a worse outcome.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Presence of Adverse Events as Measured by the Treatment Emergent Symptoms Scale (TESS)
score on a scaleLithium CarbonatePlacebo
Presence of Adverse Events as Measured by the Treatment Emergent Symptoms Scale (TESS)31.1 ± 0.5531 ± 0.66
Other pre-specifiedThe Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Agitation/Aggression" Score

The baseline serum BDNF levels as a potential baseline predictor of lithium treatment response and an increase from pre to post-treatment BDNF levels as a potential biomarker correlate of improvement in symptoms (as measured by the NPI) will be explored. The mean change of NPI "Agitation/Aggression" score as a function of BDNF level change from baseline to 12 weeks will be reported. Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · score on a scale
The Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Agitation/Aggression" Score
score on a scaleLithium CarbonatePlacebo
The Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Agitation/Aggression" Score0.71 ± 1.91-1.6 ± 2.11
Other pre-specifiedThe Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Aberrant Motor Behavior" Score

The baseline serum BDNF levels as a potential baseline predictor of lithium treatment response and an increase from pre to post-treatment BDNF levels as a potential biomarker correlate of improvement in symptoms (as measured by the NPI) will be explored. Aberrant motor behavior is characterized by repetitive movements and inability to sit still. The mean change of NPI Aberrant Motor Behavior score as a function of BDNF level change from baseline to 12 weeks will be reported. Scores range from from 0-12, with 0 being no symptoms and 12 being very frequent and severe symptoms.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · score on a scale
The Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Aberrant Motor Behavior" Score
score on a scaleLithium CarbonatePlacebo
The Relationship Between Changes in Brain-derived Neurotropic Factor (BDNF) Serum Levels and Changes in NPI "Aberrant Motor Behavior" Score0.4 ± 11.330.4 ± 1.83

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lithium Carbonate0/9 (0%)2/9 (22.2%)0/9 (0%)
Placebo0/7 (0%)0/7 (0%)0/7 (0%)
Most frequent serious events
Most frequent serious events
EventLithium CarbonatePlacebo
FallInjury, poisoning and procedural complications2/90/7

Baseline characteristics

Age, Customized
Age, Customized(Participants)Lithium CarbonatePlaceboTotal
40-55 years235
56-65 years527
66-75 years224
76-85 years000
Sex: Female, Male
Sex: Female, Male(Participants)Lithium CarbonatePlaceboTotal
Female5611
Male415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lithium CarbonatePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White9615
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Lithium CarbonatePlaceboTotal
United States9716
08

Study locations

1 site
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Nov 2022, 69 months.

Results were first posted in Feb 2025, 2 years 2 months after primary completion. A results delay was requested in Oct 2023.

Of 19 phase 2 interventional studies under Frontotemporal Dementia, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 64. This study's 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2016
First posted
Aug 10, 2016
StartActual
Jan 27, 2017
Primary completionActual
Nov 20, 2022
CompletionActual
Nov 20, 2022
Results delay requested
Oct 20, 2023
Results first posted
Feb 3, 2025
Last update
Feb 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02862210
Collaborators
Alzheimer's Drug Discovery Foundation
Responsible party
Edward D Huey, MD (Assistant Professor of Psychiatry, Columbia University) — Principal investigator
First posted
Aug 10, 2016
Start date
Jan 27, 2017
Primary completion
Nov 20, 2022
Completion
Nov 20, 2022
Results posted
Feb 3, 2025
Last update
Feb 3, 2025

Study contacts

Edward Huey, MD
principal investigator · Brown University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lithium Carbonate

Start the discussion